146 related articles for article (PubMed ID: 24024945)
1. Progress in the development of neurokinin 3 modulators for the treatment of schizophrenia: molecule development and clinical progress.
Dawson LA; Porter RA
Future Med Chem; 2013 Sep; 5(13):1525-46. PubMed ID: 24024945
[TBL] [Abstract][Full Text] [Related]
2. Novel NK(3) receptor antagonists for the treatment of schizophrenia and other CNS indications.
Simonsen KB; Juhl K; Steiniger-Brach B; Nielsen SM
Curr Opin Drug Discov Devel; 2010 Jul; 13(4):379-88. PubMed ID: 20597024
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic utility of NK3 receptor antagonists for the treatment of schizophrenia.
Dawson LA; Smith PW
Curr Pharm Des; 2010 Jan; 16(3):344-57. PubMed ID: 20109143
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel NK1/NK3 dual antagonists for the potential treatment of schizophrenia.
Catalani MP; Alvaro G; Bernasconi G; Bettini E; Bromidge SM; Heer J; Tedesco G; Tommasi S
Bioorg Med Chem Lett; 2011 Nov; 21(22):6899-904. PubMed ID: 21974957
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of potential dual NK(1)/NK(3) receptor antagonists.
Hanessian S; Babonneau V; Boyer N; Mannoury la Cour C; Millan MJ; De Nanteuil G
Bioorg Med Chem Lett; 2014 Jan; 24(2):510-4. PubMed ID: 24374277
[TBL] [Abstract][Full Text] [Related]
6. Neurokinin 3 (NK3) receptor modulators for the treatment of psychiatric disorders.
Smith PW; Dawson LA
Recent Pat CNS Drug Discov; 2008 Jan; 3(1):1-15. PubMed ID: 18221236
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
[TBL] [Abstract][Full Text] [Related]
8. Opinion: NK3 receptor antagonists: the next generation of antipsychotics?
Spooren W; Riemer C; Meltzer H
Nat Rev Drug Discov; 2005 Dec; 4(12):967-75. PubMed ID: 16341062
[TBL] [Abstract][Full Text] [Related]
9. Discovery of potent, balanced and orally active dual NK1/NK3 receptor ligands.
Peters JU; Hoffmann T; Schnider P; Stadler H; Koblet A; Alker A; Poli SM; Ballard TM; Spooren W; Steward L; Sleight AJ
Bioorg Med Chem Lett; 2010 Jun; 20(11):3405-8. PubMed ID: 20430616
[TBL] [Abstract][Full Text] [Related]
10. A decade of progress in the discovery and development of 'atypical' antipsychotics.
MacDonald GJ; Bartolomé JM
Prog Med Chem; 2010; 49():37-80. PubMed ID: 20855038
[No Abstract] [Full Text] [Related]
11. Neuropeptides and neuropeptide receptors: drug targets, and peptide and non-peptide ligands: a tribute to Prof. Dieter Seebach.
Hoyer D; Bartfai T
Chem Biodivers; 2012 Nov; 9(11):2367-87. PubMed ID: 23161624
[TBL] [Abstract][Full Text] [Related]
12. Multi-Target Approach for Drug Discovery against Schizophrenia.
Kondej M; Stępnicki P; Kaczor AA
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30309037
[TBL] [Abstract][Full Text] [Related]
13. [Evidence on the key role of the metabotrobic glutamatergic receptors in the pathogenesis of schizophrenia: a "breakthrough" in pharmacological treatment].
Pannese R; Minichino A; Pignatelli M; Delle Chiaie R; Biondi M; Nicoletti F
Riv Psichiatr; 2012; 47(2):149-69. PubMed ID: 22622251
[TBL] [Abstract][Full Text] [Related]
14. AMPA receptor-positive allosteric modulators for the treatment of schizophrenia: an overview of recent patent applications.
Ward SE; Pennicott LE; Beswick P
Future Med Chem; 2015; 7(4):473-91. PubMed ID: 25875874
[TBL] [Abstract][Full Text] [Related]
15. Neurobiological background for the development of new drugs in schizophrenia.
López-Muñoz F; Álamo C
Clin Neuropharmacol; 2011; 34(3):111-26. PubMed ID: 21586917
[TBL] [Abstract][Full Text] [Related]
16. Osanetant Sanofi-Synthélabo.
Kamali F
Curr Opin Investig Drugs; 2001 Jul; 2(7):950-6. PubMed ID: 11757797
[TBL] [Abstract][Full Text] [Related]
17. Molecular modeling of neurokinin B and tachykinin NK₃ receptor complex.
Ganjiwale AD; Rao GS; Cowsik SM
J Chem Inf Model; 2011 Nov; 51(11):2932-8. PubMed ID: 21913652
[TBL] [Abstract][Full Text] [Related]
18. Metabotropic glutamate receptor 5 in schizophrenia: emerging evidence for the development of antipsychotic drugs.
Newell KA
Future Med Chem; 2013 Sep; 5(13):1471-4. PubMed ID: 24024939
[No Abstract] [Full Text] [Related]
19. Neurokinin NK1 and NK3 receptors as targets for drugs to treat gastrointestinal motility disorders and pain.
Sanger GJ
Br J Pharmacol; 2004 Apr; 141(8):1303-12. PubMed ID: 15023866
[TBL] [Abstract][Full Text] [Related]
20. Is there still a future for neurokinin 3 receptor antagonists as potential drugs for the treatment of psychiatric diseases?
Griebel G; Beeské S
Pharmacol Ther; 2012 Jan; 133(1):116-23. PubMed ID: 21963368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
